Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Merck Kgaa ADR (MKKGY)

Merck Kgaa ADR (MKKGY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.0700 unch
on 02/28/20
27.2300 -11.60%
on 02/19/20
-2.1100 (-8.06%)
since 01/28/20
3-Month
22.6400 +6.32%
on 12/11/19
27.2300 -11.60%
on 02/19/20
+0.6100 (+2.60%)
since 11/27/19
52-Week
19.2000 +25.36%
on 05/31/19
27.2300 -11.60%
on 02/19/20
+3.4250 (+16.59%)
since 02/28/19

Most Recent Stories

More News
Global In-vitro Toxicology Testing Market (2020 to 2027) - Featuring Agilent Technologies, Abbott, Bio-Rad Laboratories & Merck KGaA Among Others

The "In-vitro Toxicology Testing Market Size, Share & Trends Analysis Report By Technology (Cell Culture, High Throughput), By Method, By Application, By End Use, By Region, And Segment Forecasts,...

A : 74.70 (-3.53%)
MKKGY : 23.9200 (-2.69%)
Global Dimethyl Carbonate Market Analysis & Trends (2018 to 2028) - Featuring Merck KGaA, Lotte Chemical, Kowa Company & Kishida Chemical Co Among Others - ResearchAndMarkets.com

The "Global Dimethyl Carbonate Market Analysis & Trends - Industry Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

MKKGY : 23.9200 (-2.69%)
Global Molecular Weight Marker Market (2020 to 2024) - Featuring Merck KGaA, New England Biolabs, Promega & QIAGEN NV Among Others - ResearchAndMarkets.com

The "Global Molecular Weight Marker Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

MKKGY : 23.9200 (-2.69%)
ReForm Biologics and MilliporeSigma Announce a Licensing Agreement for Excipient Development and Commercialization

ReForm Biologics LLC, a pharmaceutical technology company developing innovative platforms to improve biologic formulations and MilliporeSigma today announced a global license agreement and collaboration...

MKKGY : 23.9200 (-2.69%)
Competent Cells Market Analysis 2019 Along with Research Report

MarketInsightsReports has published a report entitled Global Competent Cells Market Research Report 2019 that is a detailed observation of several aspects, including the rate of growth, technological advances...

A : 74.70 (-3.53%)
MKKGY : 23.9200 (-2.69%)
QGEN : 36.31 (-0.44%)
EMD Serono Receives Positive Recommendation for MAVENCLAD® (cladribine tablets) for the treatment of Relapsing-Remitting Multiple Sclerosis from the Institut national d'excellence en santé et en services sociaux (INESSS)

This decision brings (Pr)MAVENCLAD® (cladribine tablets) closer to broader access for eligible patients living with Relapsing-Remitting Multiple Sclerosis in the province of Quebec

MKKGY : 23.9200 (-2.69%)
Wood Vinegar Market 2020 Global Analysis, Opportunities And Forecast To 2026

MKKGY : 23.9200 (-2.69%)
Proliferative Diabetic Retinopathy Market 2019 : Global Industry Size, Share, Growth, Forecasts to 2026

AGN : 187.61 (-1.01%)
MRK : 75.04 (-3.89%)
MKKGY : 23.9200 (-2.69%)
NVS : 83.69 (-2.71%)
REGN : 423.38 (-1.91%)
VRX.TO : 30.80 (-3.33%)
Genome & Company announces a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer

-- Clinical partnership of phase 1/1b combination clinical trial with Genome & Company's GEN-001, microbiome-based immuno-oncology therapy, and avelumab (BAVENCIO((R))), Merck KGaA, Darmstadt, Germany...

MKKGY : 23.9200 (-2.69%)
PFE : 32.76 (-3.93%)
Genome & Company announces a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer

Genome & Company (KONEX: 314130) is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to evaluate the...

MKKGY : 23.9200 (-2.69%)
PFE : 32.76 (-3.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade MKKGY with:

Key Turning Points

2nd Resistance Point 25.2067
1st Resistance Point 24.8933
Last Price 23.9200
1st Support Level 24.4233
2nd Support Level 24.2667

See More

52-Week High 27.2300
Fibonacci 61.8% 24.1625
Last Price 23.9200
Fibonacci 50% 23.2150
Fibonacci 38.2% 22.2675
52-Week Low 19.2000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar